Gene Therapy’s Next Big Challenge: Manufacturing
Executive Summary
As the pipeline and market for novel cell and gene therapies expands, it is time for drug developers to address other critical aspects in the logistical chain – and for these complex therapies a lot of those issues relate to manufacturing. Looking at specific cases, In Vivo has underlined the main manufacturing challenges facing cell and gene therapy developers, and highlighted methods and approaches being used to generate solutions.
You may also be interested in...
Investment Outlook For Cell And Gene Therapies Is Cautiously Optimistic
Investors at Alliance for Regenerative Medicine’s Investor Day in March 2019 were bullish on cell and gene therapies, but some worry about the market overcrowding.
Gene Therapies Make A Mark In US FDA Expedited Review Programs
More than 20 gene therapies are being developed with increased interaction under FDA’s breakthrough and regenerative medicine programs.
FDA's CMC Guidance For Investigational Gene Therapies Reflects Broader CMC Evolution
New draft document addresses issues with applying quality-by-design to gene therapies, accommodating the Common Technical Document format, as well as drug substance, cell bank and contract manufacturing issues. US FDA's Denise Gavin offers insights on agency thinking at gene therapy conference.